{
    "clinical_study": {
        "@rank": "84056", 
        "arm_group": {
            "arm_group_label": "Human-cl rhFVIII", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to collect long-term data on the inhibitor development rate of\n      Human-cl rhFVIII in previously untreated patients with severe Hemophilia A."
        }, 
        "brief_title": "Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1. Patients who completed GENA-05 in accordance with the study protocol\n\n        Exclusion Criteria:\n\n          1. Severe liver or kidney disease\n\n          2. Concomitant treatment with any systemic immunosuppressive drug;\n\n          3. Other FVIII concentrate than Human-cl rhFVIII was received between completion visit\n             of GENA-05 and start of GENA-15 (except emergency cases)."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992549", 
            "org_study_id": "GENA-15"
        }, 
        "intervention": {
            "arm_group_label": "Human-cl rhFVIII", 
            "intervention_name": "Human-cl rhFVIII", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "UC Davis Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8S4K1"
                    }, 
                    "name": "McMaster Children's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "WC1N 3JH"
                    }, 
                    "name": "Great Ormond Street Hospital for Children"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Extension Study for Patients Who Completed GENA-05 (NuProtect)- to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII", 
        "overall_contact": {
            "email": "sigurd.knaub@octapharma.com", 
            "last_name": "Sigurd Knaub, PhD", 
            "phone": "+41 5541512141"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients who develop an inhibitor", 
            "measure": "Immunogenicity", 
            "safety_issue": "Yes", 
            "time_frame": "maximum two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992549"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Octapharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Octapharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}